Letters to the Editor published on April 1, 2025, address various topics. The video content related to the letters may not be loading properly. Readers are encouraged to refresh their browsers or access alternative videos. The letters likely cover a range of opinions and perspectives on current issues and events.
Full Article
Cheaper generic Ozempic is coming to Canada after Novo Nordisk fails to maintain patent in this country
Several applications for generic semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy, are currently under review by Health Canada, as the patent for Ozempic is set to expire due to Novo Nordisk's failure to pay maintenance fees. This opens the market for cheaper alternatives, with a U.S. telehealth service planning to offer generic versions at a significant discount, potentially impacting weight-loss drug usage and social dynamics, particularly in dating. Explain It To Me...
Read more